S M Marcovina

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. pmc Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage
    Josyf C Mychaleckyj
    Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
    J Transl Med 9:91. 2011
  2. ncbi request reprint Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions
    Santica M Marcovina
    Department of Medicine, University of Washington, Northwest Lipid Research Laboratories, 2121 N 35th St, Seattle, WA 98103, USA
    Clin Chem 49:1785-96. 2003
  3. ncbi request reprint Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside
    Santica M Marcovina
    Department of Medicine, University of Washington, Seattle, Washington 98103, USA
    Curr Opin Lipidol 14:361-6. 2003
  4. ncbi request reprint A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment?
    Santica M Marcovina
    Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle, WA 98103, USA
    Semin Vasc Med 2:335-44. 2002
  5. ncbi request reprint Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools
    S M Marcovina
    Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, WA 98109, USA
    J Intern Med 261:214-34. 2007
  6. ncbi request reprint Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)
    S M Marcovina
    University of Washington, Department of Medicine, Northwest Lipid Research Laboratories, Seattle, WA 98103, USA
    Clin Chem 46:1956-67. 2000
  7. ncbi request reprint Conformation-dependent GAD65 autoantibodies in diabetes
    D Luo
    Department of Medicine, University of Washington, R H Williams Laboratory, 1959 N E Pacific Street, Box 357710, Seattle, WA 98195 7710, USA
    Diabetologia 47:1581-91. 2004
  8. doi request reprint SAA and PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction
    S Vuletic
    Department of Medicine, University of Washington, Seattle, Washington 98109, United States
    Oral Dis 14:514-9. 2008
  9. ncbi request reprint Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study
    M J McNeely
    Department of Medicine, School of Medicine, University of Washington, Box 356429, Seattle, WA 98195, USA
    Atherosclerosis 159:471-81. 2001
  10. ncbi request reprint A novel monoclonal antibody specific for the N-terminal end of GAD65
    C S Hampe
    Robert H Williams Laboratory, Department of Medicine, Box 357710, University of Washington, Seattle, 98105 7710, USA
    J Neuroimmunol 113:63-71. 2001

Detail Information

Publications38

  1. pmc Buffy coat specimens remain viable as a DNA source for highly multiplexed genome-wide genetic tests after long term storage
    Josyf C Mychaleckyj
    Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA
    J Transl Med 9:91. 2011
    ..A common protocol is to store buffy coat specimens for future DNA isolation and these may remain in frozen storage for many years. It is uncertain if the DNA remains suitable for modern genome wide association (GWA) genotyping...
  2. ncbi request reprint Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions
    Santica M Marcovina
    Department of Medicine, University of Washington, Northwest Lipid Research Laboratories, 2121 N 35th St, Seattle, WA 98103, USA
    Clin Chem 49:1785-96. 2003
    ..This report includes the most recent data presented by the workshop participants and the resulting practical and research recommendations...
  3. ncbi request reprint Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside
    Santica M Marcovina
    Department of Medicine, University of Washington, Seattle, Washington 98103, USA
    Curr Opin Lipidol 14:361-6. 2003
    ....
  4. ncbi request reprint A critical evaluation of the role of Lp(a) in cardiovascular disease: can Lp(a) be useful in risk assessment?
    Santica M Marcovina
    Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle, WA 98103, USA
    Semin Vasc Med 2:335-44. 2002
    ..Although characterization of Lp(a) in the general population is not presently justified, Lp(a) analysis in patients at risk for CHD may be warranted...
  5. ncbi request reprint Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools
    S M Marcovina
    Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, WA 98109, USA
    J Intern Med 261:214-34. 2007
    ..The optimal approach to intervention must take into consideration the risk-benefit and cost-effectiveness ratios...
  6. ncbi request reprint Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)
    S M Marcovina
    University of Washington, Department of Medicine, Northwest Lipid Research Laboratories, Seattle, WA 98103, USA
    Clin Chem 46:1956-67. 2000
    ....
  7. ncbi request reprint Conformation-dependent GAD65 autoantibodies in diabetes
    D Luo
    Department of Medicine, University of Washington, R H Williams Laboratory, 1959 N E Pacific Street, Box 357710, Seattle, WA 98195 7710, USA
    Diabetologia 47:1581-91. 2004
    ..In this study we aimed to determine whether the substitution of GAD65 with GAD67 amino acids would affect the binding of conformation-dependent GAD65 autoantibodies...
  8. doi request reprint SAA and PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction
    S Vuletic
    Department of Medicine, University of Washington, Seattle, Washington 98109, United States
    Oral Dis 14:514-9. 2008
    ..To assess whether treatment of advanced periodontal disease affects plasma levels of serum amyloid A (SAA) and phospholipid transfer protein (PLTP) activity...
  9. ncbi request reprint Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study
    M J McNeely
    Department of Medicine, School of Medicine, University of Washington, Box 356429, Seattle, WA 98195, USA
    Atherosclerosis 159:471-81. 2001
    ..In conclusion, apoB is associated with hyperlipidemia and apoE polymorphism is associated with later onset of hyperlipidemia in FCHL...
  10. ncbi request reprint A novel monoclonal antibody specific for the N-terminal end of GAD65
    C S Hampe
    Robert H Williams Laboratory, Department of Medicine, Box 357710, University of Washington, Seattle, 98105 7710, USA
    J Neuroimmunol 113:63-71. 2001
    ..Comparing the N-GAD65 mAb gene sequences with GenBank shows that the cDNAs were not reported previously...
  11. pmc Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial
    J Q Purnell
    Department of Medicine, University of Washington, Seattle 98195, USA
    JAMA 280:140-6. 1998
    ..Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment...
  12. pmc Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes
    S D Sibley
    Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle 98195, USA
    Diabetes Care 22:1165-70. 1999
    ..This population study examines the relationship between LDL density and persistent albuminuria in subjects with type 1 diabetes at the end of the Diabetes Control and Complications Trial (DCCT)...
  13. pmc Type 1 and Type 2 diabetes in Asian and Pacific Islander U.S. youth: the SEARCH for Diabetes in Youth Study
    Lenna L Liu
    Department of Pediatrics, Seattle Children s Hospital, Seattle, Washington, USA
    Diabetes Care 32:S133-40. 2009
    ..Given limited reports on diabetes among U.S. Asian and Pacific Islander youth, we describe the clinical characteristics, incidence, and prevalence of diabetes among Asian, Pacific Islander, and mixed Asian-Pacific Islander youth...
  14. ncbi request reprint The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
    Kristina M Utzschneider
    Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington and VA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes Care 31:108-13. 2008
    ..To evaluate the effect of treatment with the dipeptidyl peptidase (DPP)-4 inhibitor vildagliptin on insulin sensitivity and beta-cell function in subjects with impaired fasting glucose (IFG)...
  15. ncbi request reprint Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia
    H Kim
    Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA 98195, USA
    Clin Genet 60:188-97. 2001
    ..In conclusion, Lp(a) levels in offspring may be associated with maternal but not paternal history of CVD mortality. This parent-specific finding needs to be confirmed in other samples of high-risk families...
  16. ncbi request reprint Antibodies to glutamic acid decarboxylase and peripheral nerve function in type 1 diabetes
    R D Hoeldtke
    Department of Medicine, West Virginia University, Morgantown 26506 9159, USA
    J Clin Endocrinol Metab 85:3297-308. 2000
    ..001) and could not be attributed to GAD65Ab-related differences in glycemic control...
  17. ncbi request reprint Antibodies to GAD and glycemic control in recent-onset IDDM
    R D Hoeldtke
    Department of Medicine, West Virginia University, Morgantown 26506 9159, USA
    Diabetes Care 20:1900-3. 1997
    ..To analyze the effect of antibodies to glutamic acid decarboxylase (GAD65Ab) and islet cells (ICA512Ab) on glycemic control early in IDDM...
  18. ncbi request reprint Factors associated with serum leptin in patients with chronic kidney disease
    V Menon
    Department of Medicine, Division of Clinical Care Research, Tufts New England Medical Center, Boston, MA, USA
    Clin Nephrol 61:163-9. 2004
    ..We evaluated the independent associations of serum leptin in patients with reduced GFR...
  19. ncbi request reprint Complete cDNA encoding human phospholipid transfer protein from human endothelial cells
    J R Day
    Department of Medicine, University of Washington, Seattle 98103
    J Biol Chem 269:9388-91. 1994
    ....
  20. ncbi request reprint Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband
    G Argyropoulos
    Department of Medicine, Medical University of South Carolina, and Ralph H Johnson Veterans Affairs Medical Center, Charleston 29425, USA
    J Lipid Res 39:1870-6. 1998
    ..It is also shown that the two mutations impair both catalytic activity and expression of the circulating protein...
  21. pmc Marine omega-3 fatty acid intake: associations with cardiometabolic risk and response to weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study
    L Maria Belalcazar
    Department of Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Diabetes Care 33:197-9. 2010
    ..To examine usual marine omega-3 fatty acid (mO-3FA) intake in individuals with diabetes; its association with adiposity, lipid, and glucose control; and its changes with behavioral lifestyle intervention for weight loss...
  22. ncbi request reprint Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease
    Vandana Menon
    Department of Medicine, Division of Clinical Care Research, Tufts New England Medical Center, Boston, MA, USA
    Am J Kidney Dis 42:44-52. 2003
    ..Data are limited regarding relationships between CRP levels and glomerular filtration rate (GFR), nutritional indices, and CVD in patients with earlier stages of kidney disease...
  23. pmc Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes
    John J Albers
    Department of Medicine, Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, 401 Queen Anne Avenue North, Seattle, Washington 98109, USA
    J Clin Endocrinol Metab 93:735-42. 2008
    ..The objective of the study was to assess the prevalence and determinants of elevated apolipoprotein B (apoB) and dense low-density lipoprotein (LDL) in United States youth with type 1 or type 2 diabetes...
  24. ncbi request reprint Release of glutamate decarboxylase-65 into the circulation by injured pancreatic islet beta-cells
    Megan A Waldrop
    Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0726, USA
    Endocrinology 148:4572-8. 2007
    ..These results demonstrate that, as is true with other tissues, islet injury, at least in some circumstances, can be monitored by use of discharged, circulating proteins. GAD65 is the first such confirmed protein marker of islet injury...
  25. ncbi request reprint Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients
    Bernard G Jaar
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Adv Chronic Kidney Dis 14:304-13. 2007
    ..This study identifies several novel risk factors (eg, Lp(a) and total homocysteine) and underscores the need for further research to reduce the burden of PAD in this high-risk group of patients...
  26. ncbi request reprint C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
    Vandana Menon
    Department of Medicine, Division of Nephrology, Tufts New England Medical Center, Boston, Massachusetts 02111, USA
    Kidney Int 68:766-72. 2005
    ..There are limited data evaluating the relationships between CRP, albumin, and outcomes in chronic kidney disease (CKD) stages 3 and 4...
  27. ncbi request reprint Rosiglitazone increases LDL particle size and buoyancy and decreases C-reactive protein in patients with type 2 diabetes on statin therapy
    Dahong Yu
    GlaxoSmithKline, King of Prussia, PA 19406, USA
    Diab Vasc Dis Res 3:189-96. 2006
    ..However, the increase in IDL may be proatherogenic and must be considered when assessing the benefits of rosiglitazone...
  28. ncbi request reprint Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study
    J Craig Longenecker
    Johns Hopkins University, Baltimore, MD 21205, USA
    Circulation 106:2812-8. 2002
    ..Previous studies suggest that high Lp(a) levels and small apolipoprotein(a) [apo(a)] isoform size are associated with ASCVD, but none have investigated the relationship between Lp(a) level, apo(a) size, and mortality...
  29. ncbi request reprint Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus
    Martin I Freed
    GlaxoSmithKline, Collegeville, Pennsylvania 19426, USA
    Am J Cardiol 90:947-52. 2002
    ....
  30. ncbi request reprint Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity
    Marlys L Koschinsky
    Department of Biochemistry, Queen s University, Kingston, Ontario, Canada
    Curr Opin Lipidol 15:167-74. 2004
    ..Whereas many pathogenic mechanisms have been proposed for lipoprotein(a), it remains to be conclusively demonstrated which mechanisms are relevant to human disease...
  31. ncbi request reprint A role for apolipoprotein(a) in protection of the low-density lipoprotein component of lipoprotein(a) from copper-mediated oxidation
    Bruce C Hill
    Department of Biochemistry, Queen s University, Kingston, Ont, Canada K7L 3N6
    Arch Biochem Biophys 412:186-95. 2003
    ....
  32. ncbi request reprint Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease
    Gregory T Jones
    Department of Medical and Surgical Sciences, University of Otago, Dunedin, New Zealand
    Clin Chem 53:679-85. 2007
    ..This study aimed to investigate Lp(a) risk association for 4 different types of vascular disease (including CAD) within a predominantly white population...
  33. ncbi request reprint Apolipoprotein A1 and B
    Allan D Sniderman
    Mike Rosenbloom Laboratory for Cardiovascular Research, Room H7 22, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
    Clin Lab Med 26:733-50. 2006
    ....
  34. ncbi request reprint Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces
    Mark A Hancock
    Department of Biochemistry, Queen s University, Kingston, Ontario K7L 3N6, Canada
    J Biol Chem 278:23260-9. 2003
    ..The latter complex exhibits a reduced turnover number, thereby accounting for inhibition of plasminogen activation in the presence of apo(a)/Lp(a)...
  35. ncbi request reprint High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients
    J Craig Longenecker
    Johns Hopkins University, Baltimore, Maryland, USA
    J Am Soc Nephrol 16:1794-802. 2005
    ..Both LMW apo(a) size and high Lp(a) level predict ASCVD risk in dialysis patients, but the association of ASCVD with LMW isoforms is stronger than the association with high Lp(a) concentration...
  36. ncbi request reprint Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro
    Simona Vuletic
    Department of Medicine, Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, Washington 98109 4517, USA
    J Neurosci Res 80:406-13. 2005
    ..The findings of reduced PLTP activity in AD CSF, and the observation that PLTP can influence apoE secretion in astrocytes suggest a potential link between alterations in the brain lipid metabolism and AD pathogenesis...
  37. ncbi request reprint First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay--Lp(a) SRM 2B
    Francesco Dati
    IVD Consulting, Marburg, Germany
    Clin Chem Lab Med 42:670-6. 2004
    ....
  38. ncbi request reprint Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models
    Michael B Boffa
    Department of Biochemistry, Queen s University, Kingston, Ontario, Canada
    Clin Biochem 37:333-43. 2004
    ..The recent construction of transgenic apo(a) rabbits is a particularly promising development in view of the excellent utility of the rabbit as a model of advanced atherosclerosis...